Eli Lilly's VERVE-102 base editor reduced PCSK9 by up to 88% and LDL-C by up to 62% in early study, with durable effects positioning it as a potential one-time treatment for hypercholesterolemia — directly competing with chronic PCSK9 inhibitors. Lilly is prepping a Phase 2 launch, creating a medium-term catalyst path that could validate a major new pipeline asset at a time when the stock has lagged peers.